Medgenics Announces Results of 2013 Annual Meeting of Stockholders

Before you go, we thought you'd like these...
Before you go close icon

Medgenics Announces Results of 2013 Annual Meeting of Stockholders

MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the "Company" or "Medgenics"),,the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, today announces that all resolutions proposed at the Company's Annual Meeting of Stockholders held yesterday were duly passed.

Each of the current directors of the Company, Dr. Sol J. Barer, Dr. Eugene A. Bauer, Mr. Isaac Blech, Dr. Alastair Clemow, Mr. Joseph J. Grano, Jr., Mr. Joel S. Kanter, Dr. Stephen D. McMurray and Dr. Andrew L. Pearlman, was reelected to the Board of Directors.


Stockholders also approved an amendment of the Company's Stock Incentive Plan, increasing the number of shares authorized to be issued under the plan by 1,700,000 shares.

Stockholders also approved, on an advisory basis, the compensation of the executive officers of the Company. Additionally, the option to request the stockholders to vote, on an advisory basis, on executive compensation every three years received the most votes cast.

Stockholders also ratified the appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, to serve as the Company's independent registered public accounting firm for the year ended December 31, 2013.

Final voting tallies are subject to certification by the Company's inspector of elections and will be included in the Company's report, which is to be filed with the Securities and Exchange Commission within the next week.

About Medgenics

Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis C and hemophilia.



Medgenics, Inc.
Dr. Andrew L. Pearlman
Phone: +972 4 902 8900
andrew.pearlman@medgenics.com
or
LHA
Anne Marie Fields
Phone: 212-838-3777
afields@lhai.com
@LHA_IR_PR
or
Abchurch Communications

Adam Michael/Joanne Shears/Jamie Hooper
Phone: +44 207 398 7719
jamie.hooper@abchurch-group.com
or
Nomura Code Securities (NOMAD & Joint Broker)
Jonathan Senior/Giles Balleny
Phone: +44 207 776 1200
or
SVS Securities plc (Joint Broker)
Alex Brearley
Phone: +44 207 638 5600

KEYWORDS:   United States  North America  California  Middle East  Israel

INDUSTRY KEYWORDS:

The article Medgenics Announces Results of 2013 Annual Meeting of Stockholders originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners